BETA: Please send your feedback!
Innoviva
INVA:NAS
Pharmaceuticals: Other
$0
SMALL cap
$13.65
(1.24%)
-0.03%
since start of 2020
8.78
About
Pharmaceuticals: Other
Founded 1996
Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Brisbane, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| P. Roy Vagelos, MD | Founder | Male |
| Wesley D. Sterman, MD, MBA | Founder | Male |
| Jim B. Tananbaum, MD, MBA | Founder | Male |
| William H. Waltrip | Chairman | Male |
| George M. Whitesides, PhD | Founder | Male |
| Michael W. Aguiar, MBA | President, Chief Executive Officer & Director | Male |
| Eric d'Esparbes | Chief Financial Officer & Senior Vice President | Male |
| Mathai Mammen, MD, PhD | Founder | Male |
| John Hampton Griffin, PhD | Founder | Male |
| Theodore L. Witek, Jr., PhD | Chief Scientific Officer & Senior Vice President | Male |
Mindful Investing Summary
Innoviva - Competitors and Related Companies
How Innoviva stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.
Innoviva
INVA:NAS
Pharmaceuticals: Other
$0
SMALL cap
$13.65
(1.24%)
-0.03%
since start of 2020
8.78
Medicines
MDCO:NAS
Pharmaceuticals: Other
$6.77bn
MID cap
$84.90
(0.00%)
0%
since start of 2020
-27.32
Mylan
MYL:NAS
Pharmaceuticals: Generic
$7.81bn
LARGE cap
$15.14
(0.77%)
-0.23%
since start of 2020
550.55
Johnson & Johnson
JNJ:NYS
Pharmaceuticals: Major
$377.68bn
MEGA cap
$143.26
(5.78%)
-0.02%
since start of 2020
25.08
Merck
MRK:NYS
Pharmaceuticals: Major
$207.01bn
MEGA cap
$81.62
(3.06%)
-0.10%
since start of 2020
21.26
Pfizer
PFE:NYS
Pharmaceuticals: Major
$191.95bn
MEGA cap
$34.60
(0.99%)
-0.12%
since start of 2020
11.85